{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:54:25Z","timestamp":1782334465937,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cmi.2026.05.049","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:39:43Z","timestamp":1780936783000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing dalbavancin dosing for complicated methicillin-resistant Staphylococcus aureus infections: a multicentre population pharmacokinetic study"],"prefix":"10.1016","author":[{"given":"Manjunath P.","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giorgio","family":"Cojutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"De Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Zamparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Meschiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Prezzavento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Zammarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.05.049_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","article-title":"Dalbavancin: A novel lipoglycopeptide antibiotic with extended activity against gram-positive infections","volume":"4","author":"Smith","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2026.05.049_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.11641","article-title":"Comparative effectiveness of long-acting lipoglycopeptides vs standard-of-care antibiotics in serious bacterial infections","volume":"8","author":"Goodman-Meza","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2026.05.049_bib3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s40261-025-01486-z","article-title":"Budget impact and financial analysis of outpatient dalbavancin in an urban, non-teaching, community hospital","volume":"45","author":"Raja","year":"2025","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.cmi.2026.05.049_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/ajhp\/zxaf301","article-title":"Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections","volume":"83","author":"Crocker","year":"2026","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.cmi.2026.05.049_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01830-24","article-title":"Usefulness of a hub-and-spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections","volume":"69","author":"Cojutti","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.049_bib6","doi-asserted-by":"crossref","first-page":"ofae315","DOI":"10.1093\/ofid\/ofae315","article-title":"Simulated target attainment of multidose regimens of dalbavancin for prolonged durations of therapy","volume":"11","author":"Volk","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.05.049_bib7","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/jac\/dkaf132","article-title":"Effect of body mass index on the timing of therapeutic drug monitoring\u2013guided dalbavancin dosing in patients with osteoarticular infections","volume":"80","author":"Cattaneo","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.05.049_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106960","article-title":"Expert opinion on dose regimen and therapeutic drug monitoring for long-term use of dalbavancin: Expert review panel","volume":"62","author":"Senneville","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2026.05.049_bib9","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0091270005280378","article-title":"Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide","volume":"45","author":"Buckwalter","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.049_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin population pharmacokinetic modeling and target attainment analysis","volume":"9","author":"Carrothers","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cmi.2026.05.049_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00023-24","article-title":"Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular and periprosthetic joint infections","volume":"68","author":"Cattaneo","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.049_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107038","article-title":"Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections","volume":"63","author":"Cojutti","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2026.05.049_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106773","article-title":"A descriptive case series of the relationship between maintenance of conservative PK\/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections","volume":"61","author":"Gatti","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2026.05.049_bib14","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.05.049_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.7326\/M20-4366","article-title":"Development and validation of a modified full age spectrum creatinine-based equation to estimate glomerular filtration rate: A cross-sectional analysis of pooled data","volume":"174","author":"Pottel","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2026.05.049_bib16","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"10.1016\/j.cmi.2026.05.049_bib17","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/cpt.2179","article-title":"Antimicrobial dosing in specific populations and novel clinical methodologies: Kidney function","volume":"109","author":"Pai","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2026.05.049_bib18","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/cpt.2181","article-title":"Antimicrobial dosing in specific populations and novel clinical methodologies: Obesity","volume":"109","author":"Pai","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2026.05.049_bib19","series-title":"Clinical pharmacology review. Dalvance NDA 021-883","author":"He","year":"2013"},{"key":"10.1016\/j.cmi.2026.05.049_bib20","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1093\/jac\/dkac131","article-title":"Determination of plasma protein binding of dalbavancin","volume":"77","author":"Turner","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.05.049_bib21","author":"Johnson"},{"key":"10.1016\/j.cmi.2026.05.049_bib22","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1128\/AAC.01717-15","article-title":"Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.049_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106445","article-title":"Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: A proof-of-concept","volume":"58","author":"Cojutti","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2026.05.049_bib24","doi-asserted-by":"crossref","first-page":"dkag039","DOI":"10.1093\/jac\/dkag039","article-title":"Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500 mg at days 1, 15 and 43 in bone and joint or cardiovascular infection","volume":"81","author":"Lin","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.05.049_bib25","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/ajhp\/zxae317","volume":"82","author":"St Peter","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.cmi.2026.05.049_bib26","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/antibiotics13111103","article-title":"Model-based dose identification of dalbavancin for long-term suppressive outpatient treatment of ventricular assist device infections","volume":"13","author":"Chiriac","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2026.05.049_bib27","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26003125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26003125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:42:29Z","timestamp":1782333749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26003125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"alternative-id":["S1198743X26003125"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.05.049","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing dalbavancin dosing for complicated methicillin-resistant Staphylococcus aureus infections: a multicentre population pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.05.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}